The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...
Panelists discuss how CARTITUDE-4 demonstrated superior progression-free survival and overall response rates with ...
During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...
Panelists discuss how to address practical challenges in delivering chimeric antigen receptor (CAR) T cell therapy, including patient selection, bridging therapy, manufacturing delays, access barriers ...
The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...
The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline ...
An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate ...
A panelist discusses how second-line treatment options for kidney cancer have evolved through multiple clinical trials ...
During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...
The FDA has granted a priority review to dordaviprone for treating patients with recurrent H3K27M-mutant diffuse glioma, a ...
Shilpa Gupta, MD, discusses the key takeaways from the long-term outcomes of the JAVELIN Bladder 100 trial for community ...
Based on data from the Beamion LUNG-1 trial, the FDA granted a priority review to zongertinib for patients with HER2-mutant ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback